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Rituximab in treatment-resistant CIDP
with antibodies against paranodal proteins
ABSTRACT
Objective: To describe the response to rituximab in patients with treatment-resistant chronic
inflammatory demyelinating polyneuropathy (CIDP) with antibodies against paranodal proteins
and correlate the response with autoantibody titers.
Methods: Patients with CIDP and IgG4 anti–contactin-1 (CNTN1) or anti–neurofascin-155
(NF155) antibodies who were resistant to IV immunoglobulin and corticosteroids were treated
with rituximab and followed prospectively. Immunocytochemistry was used to detect anti-CNTN1
and anti-NF155 antibodies and ELISA with human recombinant CNTN1 and NF155 proteins was
used to determine antibody titers.
Results: Two patients had a marked improvement; another patient improved slightly after 10
years of stable, severe disease; and the fourth patient had an ischemic stroke unrelated to treat-
ment and was lost to follow-up. Autoantibodies decreased in all patients after rituximab
treatment.
Conclusions: Rituximab treatment is an option for patients with CIDP with IgG4 anti-CNTN1/
NF155 antibodies who are resistant to conventional therapies.
Classification of evidence: This study provides Class IV evidence that rituximab is effective for pa-
tients with treatment-resistant CIDP with IgG4 anti-CNTN1 or anti-NF155 antibodies. Neurol
Neuroimmunol Neuroinflamm 2015;2:e149; doi: 10.1212/NXI.0000000000000149
GLOSSARY
CIDP 5 chronic inflammatory demyelinating polyneuropathy; CNTN1 5 contactin-1; IVIg 5 IV immunoglobulin; MuSK 5
muscle-specific tyrosine kinase; NF155 5 neurofascin-155; ONLS 5 Overall Neuropathy Limitations Scale; PEx 5 plasma
exchange; PLA2R 5 M-type phospholipase A2 receptor; R-ODS 5 Rasch-built Overall Disability Scale.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a heterogeneous autoimmune
neuropathy.1 A subset of patients with CIDP with homogeneous phenotypic features have
antibodies against node of Ranvier proteins, such as contactin-1 (CNTN1) and neurofascin-
155 (NF155).2–5 CNTN1 is a paranodal protein that is essential to organize the axo-glial
junction and preserve node of Ranvier function.6 We previously reported that patients with
antibodies against CNTN1 present with an aggressive neuropathy with a predominantly motor
phenotype, axonal damage at onset, and, in contrast to most patients with CIDP, a poor
response to IV immunoglobulin (IVIg).2 It is important that the anti-CNTN1 antibodies in
these patients are of the IgG4 isotype, which preliminary pathologic reports7 and in vitro
experiments suggest may be pathogenic.8 NF155 is the glial counterpart of CNTN1 and
also plays an essential role in node of Ranvier structure and function.9 We have shown that
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anti-NF155 antibodies are associated with a
specific CIDP phenotype characterized by pre-
dominantly distal motor involvement and
prominent intention tremor. The antibodies
are also of the IgG4 isotype and these patients
also have poor response to IVIg.3
Diseases mediated by antibodies of the
IgG4 isotype, such as myasthenia gravis with
anti–muscle-specific tyrosine kinase (MusK)
antibodies, pemphigus vulgaris, and anti–M-
type phospholipase A2 receptor (PLA2R) idio-
pathic membranous nephropathy, respond well
to B cell–depleting therapies. This response ap-
pears even in patients resistant to immunosup-
pressant drugs and is frequently associated with a
profound and sustained depletion of autoanti-
bodies.10–12 Considering this, our study aimed to
evaluate the response to rituximab in the subset
of patients with treatment-resistant CIDP with
IgG4 anti-CNTN1 or anti-NF155 antibodies
and to determine whether clinical response is
associated with a change in autoantibody titer.
METHODS Patients and samples. We included all patients
seen in our clinics and those from other Spanish centers meeting
the European Federation of Neurological Societies/Peripheral
Nerve Society task force diagnostic criteria13 for CIDP who har-
bored antibodies against either CNTN1 or NF155 and were
resistant to IVIg and corticosteroids. Rituximab was offered to
these patients as an off-label treatment following our institution’s
protocol for compassionate use of off-label drugs. Patients
received 375 mg/m2 once weekly for 4 weeks followed by
1 dose per month for 2 additional doses. Additional rituximab
cycles were administered 1 year after treatment in patients not
achieving full recovery.
Clinical appointments and blood sampling were scheduled
every 3 months during the first year and every 6 months thereaf-
ter. Overall Neuropathy Limitations Scale (ONLS)14 and Rasch-
built Overall Disability Scale (R-ODS)15 scores were collected
prospectively.
Patients that remained significantly disabled (ONLS $5)
despite treatment with IVIg and corticosteroids were classified
as treatment resistant.
Data were recorded in a coded database.
Standard protocol approvals, registrations, and patient
consents. Informed consent for study participation was obtained
from all patients under a protocol approved by the Ethics Com-
mittee of the Hospital de la Santa Creu i Sant Pau.
Anti-CNTN1 and anti-NF155 antibody detection and
titration. Serum antibodies against CNTN1 or NF155 were de-
tected by immunocytochemistry using human CNTN1- or
NF155-transfected HEK293 cells, as previously described.2,3
ELISA was used for autoantibody isotype identification and
titration, as previously described.3,8 A sample was considered pos-
itive when the optical density was higher than that of the average
for healthy donors (n 5 8) plus 4 SDs. All samples were tested
simultaneously. To control for nonspecific IgG titer variation, all
samples were also tested with VaccZyme ELISA (Binding Site,
Barcelona, Spain) for anti–tetanic toxoid antibodies, following
the manufacturer instructions. Anti-tetanic antibody levels are
presented in IU per mL.
Classification of evidence. The primary objectives of our
study were to describe the response to rituximab in patients with
treatment-resistant CIDP with antibodies against paranodal
proteins and to correlate the response with autoantibody titers.
This study provides Class IV evidence that rituximab is
effective for patients with treatment-resistant CIDP with IgG4
anti-CNTN1 or anti-NF155 antibodies.
RESULTS We identified 9 patients harboring anti-
bodies against CNTN1 or NF155 meeting inclusion
criteria. Four patients were from our clinics (6.5% of
all patients with CIDP) and 5 (of 32, 15.6%) were
from different Spanish centers in which anti-
CNTN1 or NF155 antibodies were suspected
because the patients were either IVIg resistant or
their clinical features matched patients that were
previously described with these antibodies.
Of the 9 patients, 2 died (both anti-CNTN11,
patients 8 and 9), 1 had a complete response to cor-
ticosteroids (anti-CNTN11, patient 7), and 6 were
treatment resistant. One of these patients (patient 6,
anti-NF1551) was excluded because she had previ-
ously received rituximab for a marginal zone B cell
lymphoma. Another patient (patient 5, anti-
NF1551) declined rituximab treatment. The 4 re-
maining patients (2 anti-CNTN11, patients 1 and 4;
2 anti-NF1551, patients 2 and 3) were included in
the study and treated with rituximab. The clinical
features of these patients have been previously re-
ported.2,3 Three of the patients improved after ritux-
imab treatment in both R-ODS and ONLS scores.
Patients 1 and 2 were both severely disabled and had
substantial improvement that persisted at 1 year. Nei-
ther had responded to previous therapies except for a
transient response to plasma exchange (PEx) that did
not last longer than 2 months. Rituximab treatment
was scheduled immediately after the last PEx course.
Patient 1 improved dramatically after rituximab treat-
ment and was able to be withdrawn from other treat-
ments. He has resumed all previous activities (figure
1A) and has not relapsed to date (16 months after
treatment). Patient 2 had substantial improvement
with mild residual disability (predominantly distal
leg weakness) (figure 1C). Disease duration in these
2 patients was less than 1 year at the initiation of
rituximab. Patient 3 improved slightly (figure 1E).
This patient had significantly longer disease duration
(15 years) than patients 1 and 2 and an EMG showed
features consistent with axonal degeneration. This
patient did not receive PEx prior to rituximab as he
had not responded to a prior PEx course after 3 suc-
cessful PEx courses at disease onset. Patient 4 was
removed from the study because she had a cardioem-
bolic middle cerebral artery infarction soon after
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the first rituximab dose that resulted in severe disa-
bility and institutionalization, precluding follow-up
evaluations.
Anti-CNTN1 and anti-NF155 antibodies were
predominantly of the IgG4 isotype in all 4 patients, as
previously described.3,8 Anti-CNTN1 and anti-NF155
Figure 1 Clinical status and autoantibody titers in rituximab-treated patients with anti-CNTN1/NF155
chronic inflammatory demyelinating polyneuropathy
Patient 1 improved dramatically after rituximab treatment in both Rasch-built Overall Disability Scale (R-ODS) and Overall
Neuropathy Limitations Scale (ONLS) scores, reaching full recovery at 12 months (A). Anti–contactin-1 (CNTN1) antibody
titers decreased rapidly and were undetectable as early as 6 months after treatment, whereas anti–tetanic toxoid (TT)
antibodies remained stable after treatment (B). Patient 2 hadmarked improvement after rituximab treatment in both R-ODS
and ONLS scores, althoughmild leg distal weakness persisted (C). Anti–neurofascin-155 (NF155) antibody titers decreased
rapidly and remained low 18 months after treatment. Anti-TT antibodies, however, decreased immediately after treatment
and stabilized thereafter (D). Patient 3 improved slightly after rituximab treatment in both R-ODS and ONLS scores,
although marked disability persisted (E). This patient had a significantly longer disease duration (more than 15 years) and
secondary axonal damage. Nevertheless, anti-NF155 antibody titers decreased rapidly after treatment and stabilized at a
titer of 1/900. An additional rituximab course further decreased anti-NF155 antibody titers. Anti-TT antibodies remained
stable after treatment (F). Arrows represent additional rituximab courses.
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IgG4 antibody titers decreased significantly in all pa-
tients after rituximab treatment. IgG4 autoantibody
titers at 6 months were significantly lower or undetect-
able by ELISA compared with baseline in the
rituximab-treated patients. In contrast, anti–tetanic tox-
oid autoantibodies remained stable or decreased slightly
after rituximab treatment (figure 1, B, D, and F).
To investigate whether the decrease in autoanti-
body titers was related to treatment or to the normal
evolution of a monophasic immune response, we per-
formed the following studies. First, we tested anti-
NF155 antibodies in patient 3 from a serum sample
extracted 10 years before rituximab treatment. Titers
were similar to those at inclusion (figure 1F). Unfor-
tunately, pretreatment autoantibody stability could
not be tested in patients 1 and 2 (as in patient 3)
because the only prerituximab samples available were
the ones shown in figure 1. Second, in patient 5, who
declined rituximab treatment, both autoantibody titers
and clinical status measured by R-ODS remained sta-
ble after 1 year of follow-up despite treatment with
corticosteroids and methotrexate (figure 2A). Finally,
in the patient (patient 7) who met inclusion criteria
but did not receive rituximab due to a complete
response to corticosteroids, the clinical response was
associated with a highly significant reduction of auto-
antibody titers after 1 year (figure 2B).
DISCUSSION Our study reinforces the diagnostic
and therapeutic importance of identifying patients
with CIDP harboring IgG4 anti-CNTN1/NF155.
These antibodies are biomarkers of a subpopulation
of patients with CIDP who are resistant to IVIg
and steroids but who can have marked and even
dramatic improvement with rituximab.
The high proportion of IVIg-resistant patients
with anti-CNTN1 or anti-NF155 antibodies2,3,16 is
in contrast to the high IVIg response rates seen in
typical CIDP17 and led us to consider alternative
treatments. Rituximab is associated with long-
lasting and profound responses in other IgG4-
mediated diseases, suggesting that it could be effective
in patients with IgG4 anti-CNTN1/NF155 who are
resistant to IVIg and corticosteroids. In our cohort,
rituximab resulted in a dramatic response in 2 pa-
tients and a slight improvement in a third. The fact
that disease duration was significantly shorter in the
patients who had marked responses suggests that early
treatment may be important in order to avoid perma-
nent nerve damage. This hypothesis is supported by
the fact that the 2 marked responders had also re-
sponded to PEx whereas patient 3, after 3 successful
PEx cycles, had become PEx resistant. As response
might vary depending on disease duration or axonal
damage, early detection of these patients may have
prognostic implications.
Some case reports and small case series describe
CIDP improvement with rituximab,18 but there is lim-
ited evidence to recommend its systematic use. Despite
the small number of patients, our study illustrates how
the IgG4 isotype of the antibodies helped in therapy
selection based on pathophysiologic homology with
other diseases rather than CIDP-specific features.
The recent report by Doppler et al.7 briefly describing
1 IgG4 anti-CNTN11 patient who also responded to
rituximab supports our findings.
Autoantibody titers decreased substantially in all pa-
tients treated with rituximab regardless of the degree of
response, whereas antibodies against tetanic toxoid
(mainly IgG1) remained stable. Autoantibody titers
were also lowered substantially in the only patient from
our series fully responding to corticosteroids. Of inter-
est, a correlation between antibody titers and clinical sta-
tus has also been found in patients with myasthenia
gravis and antibodies to MuSK (IgG4 isotype) but
not in patients with antibodies against acetylcholine
receptor (IgG1-3 isotypes).11 This phenomenon seems
to be IgG isotype–dependent, as it occurs in other
Figure 2 Clinical and autoantibody status of 2
CNTN1 or NF1551 patients not
receiving rituximab
Despite corticosteroids and methotrexate treatment,
patient 5 remained significantly disabled but declined to
be treated with rituximab and his clinical status and autoan-
tibody levels remained stable (A). Patient 7 is the only
patient from our cohort fully responding to corticosteroids.
Clinical scales improved clearly and anti–contactin-
1 (CNTN1) antibodies disappeared (B). NF155 5 neurofas-
cin-155; R-ODS 5 Rasch-built Overall Disability Scale.
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IgG4-mediated diseases such as pemphigus vulgaris and
anti-PLA2R idiopathic membranous nephropathy.10,19
CIDP is a rare disease and patients with IgG4 anti-
CNTN1/NF155 CIDP account for less than 10% of
all patients with CIDP.2,3,16 Thus the number of pa-
tients with CIDP and IgG4 antibodies is very small,
which is the main limitation of our study. However,
the magnitude and potential relevance of the findings
in these few cases suggest that testing for these anti-
bodies can have important therapeutic implications.
Clinical and electrophysiologic diagnostic criteria are
undoubtedly essential for detecting patients with
inflammatory neuropathies so that treatment can be
promptly initiated. However, the identification of
specific biomarkers should be a research priority in
a tissue-specific and heterogeneous disease such as
CIDP.20 Infrequent antibodies may define small
CIDP subtypes that, in aggregate, represent a relevant
proportion of all patients with CIDP. Identifying
novel clinical-immunologic associations will refine
the diagnosis of CIDP, guide treatment selection,
and help monitor response to treatment.
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